CSTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Castle Biosciences Inc (CSTL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive analyst ratings and price target increases, the recent financial performance is weak, with declining revenue, net income, and EPS. Additionally, technical indicators suggest the stock is oversold, but there are no significant trading signals or catalysts to indicate an immediate entry point. A cautious 'hold' is recommended until more favorable signals or financial improvements emerge.
The stock is oversold with RSI_6 at 13.272, indicating potential for a rebound. However, the MACD histogram is negative (-0.917) and contracting, signaling bearish momentum. Moving averages are converging, and the stock is trading near its support level (S1: 32.016).
Analysts have consistently raised price targets, with the latest targets ranging from $43 to $50, reflecting strong confidence in the stock's long-term potential. The stock is trading at a relatively low valuation (2.6x sales), which analysts consider attractive.
The company's Q3 2025 financials show a decline in revenue (-3.19% YoY), net income (-122.08% YoY), and EPS (-125.00% YoY). Gross margin also dropped by 5.58% YoY. No recent news or significant trading trends from hedge funds, insiders, or Congress trading data.
In Q3 2025, revenue dropped to $83.04M (-3.19% YoY), net income fell to -$501K (-122.08% YoY), and EPS declined to -0.02 (-125.00% YoY). Gross margin decreased to 74.74%, down 5.58% YoY, indicating weakening profitability.
Analysts maintain a positive outlook on CSTL, with multiple firms raising price targets recently. KeyBanc raised the target to $50, Guggenheim to $47, and Canaccord to $50, all with Buy or Overweight ratings. Analysts highlight the stock's strong risk-reward profile and potential for share price appreciation.
